RecruitingPhase 4NCT07177300

Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)

Studying Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Children's Hospital Medical Center, Cincinnati
Principal Investigator
Charles T. Quinn, Professor of Pediatrics, M.D., M.S.
Children's Hospital Medical Center, Cincinnati
Intervention
PK-optimized oral hydroxyurea at MTD until 15 years of age.(drug)
Enrollment
50 enrolled
Eligibility
All sexes
Timeline
20242028

Study locations (1)

Collaborators

Greater Cincinnati Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07177300 on ClinicalTrials.gov

Other trials for Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome

← Back to all trials